Ocugen, Inc. (OCGN)
After hours:
| Previous close | 2.1700 |
| Open | 2.1500 |
| Bid | 2.2000 x 29200 |
| Ask | 2.2400 x 38500 |
| Day's range | 2.1100 - 2.2900 |
| 52-week range | 1.6700 - 17.6500 |
| Volume | |
| Avg. volume | 9,250,825 |
| Market cap | 476.613M |
| Beta (5Y monthly) | 4.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3470 |
| Earnings date | 04 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.38 |
- Motley Fool
2 Struggling Stocks That Aren't Likely to Recover Anytime Soon
Two such stocks that could struggle for a long time to come are Ocugen (NASDAQ: OCGN) and Peloton Interactive (NASDAQ: PTON). Up until now, it has had nothing to show for its agreement with Bharat Biotech to help commercialize the Indian-based company's COVID-19 vaccine, Covaxin. Its agreements were to share in the profits of the vaccine in the Canadian and U.S. markets -- but Covaxin isn't approved for use in either country.
- Zacks
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
- GlobeNewswire
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
NeoCart® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines MALVERN, Pa., May 24, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that it is diversifying its innovative pipeline by introducing a Phase 3, cell therapy platform technology called NeoCart® (
